Abstract
The optimal pharmacologic regimen for patients with ST-elevation myocardial infarction (STEMI) is under debate. The GUSTO-V trial failed to demonstrate that the addition of abciximab to reteplase reduced mortality, whereas the ASSENT-3 trial demonstrated a reduction in combined death, MI, and recurrent ischemia when either abciximab or enoxaparin …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
